Hello, everyone. Welcome to the People's Reception Hall. Since this year, in the face of some unexpected changes in the international and domestic environment, various departments across China have continued to make efforts to stabilize foreign investment, helping enterprises to solve problems such as resuming production and logistics transportation. In order to further reflect the current situation of the development of foreign-funded enterprises in China and show the opportunities provided by a more open Chinese market for the development of foreign-funded enterprises. The column of "Foreign investment talks about confidence" will invite executives of foreign-funded enterprises to the People's Daily Online to show the current situation of the development of foreign-funded enterprises in China, China's opportunities, world sharing and other topics. In this program, we invited Wang Lei, Executive Vice President of AstraZeneca Global, President of International Business and President of China, to the People's Daily Online to talk about what strategic thinking foreign enterprises have about deeply cultivating the Chinese market? First of all, welcome President Wang.

hello everyone.

With the normalization of epidemic prevention and control, China's economy has shown a recovery trend. First of all, we would also like to ask President Wang what is AstraZeneca's view on the statement that China's economy is still resilient?

AstraZeneca is still full of confidence in China's economy. Although there are still many difficulties, the Chinese government has issued a series of important measures, including the Foreign Investment Law issued last year. In addition, the tax reduction policy of the State Council has also helped enterprises effectively.

In addition, the provincial and municipal governments of our country have provided excellent services and support for enterprises in terms of restoring supply chains and resuming production, and local governments have spared no effort in promoting high-quality development. We are still very optimistic and confident about China's huge market, the resilience of China's economy, the center of manufacturing industry, including the science and innovation center we are building, our investment in high-tech and green economy, and the future of China's economy.

Thank you, Mr. Wang. How do you feel about the changes in the business environment in recent years?

The Chinese government has launched many measures in the protection and encouragement of foreign investment. The protection of intellectual property rights is also very strong. The local governments of all provinces and cities are very open to the approval of business environment and simple enterprise procedures, including the approval of the directory list.

In addition, the Chinese government, especially the local governments, including the central government departments, may know this industry very well, and may be the most knowledgeable government in the world that we have seen. I believe that with the support of such a knowledgeable government and a very open investment environment, I believe that this business environment may be world-class.

Thank you, Mr. Wang. Of course, you just talked about your views on the steady development of China's economy and your assessment of the business environment. We also want to know what is attracting AstraZeneca to continuously increase its investment in China?

It may have been 30 years since AstraZeneca entered China. The first time AstraZeneca entered China was to see China's 1 billion population and huge medical demand. It is hoped that new drugs developed around the world can be listed in China at the same time. At present, the national policy is very encouraging, the Food and Drug Administration has also expedited the approval, and the Medical Insurance Bureau has expedited the reimbursement of these new drugs so that they can be used by the people. I think this is the first stage.

In the second stage, AstraZeneca is based on the fact that China is not only an important market, but also an important manufacturing center. AstraZeneca has put the most advanced factories in the world into China, including Wuxi and Taizhou in Jiangsu Province. Recently, we also set up our new factories for inhalation drugs in Qingdao. After the epidemic ended, we kept going at the third multinational leaders' summit and announced such an industrial investment certificate announcement in Qingdao. This is the second stage. China is a manufacturing center with high quality, obvious cost advantages and high labor level.

In the third stage, China will promote high-quality development, build a science and innovation center, and make it possible for patients around the world to use new drugs invented in China in the future. AstraZeneca, Fabojin in Yizhuang, Beijing, and Hehuang Pharmaceutical in Shanghai jointly developed two new drugs, both of which were first launched in China and are now reaching the world. The development of new drugs in China to benefit patients around the world is not a dream, but a reality. China's policy of promoting science and technology innovation centers, a large number of scientists began to start their own businesses, and research and development has sprung up like mushrooms. Therefore, in this regard, I want to make it possible for patients around the world to use new drugs invented and manufactured in China. Therefore, AstraZeneca finds China particularly attractive in this regard.

Thank you, Mr. Wang. Of course, you just mentioned that AstraZeneca has some significant advantages in both R&D and manufacturing in China. What strategic thinking does AstraZeneca have about deeply cultivating China?

AstraZeneca is sure that China will continue to maintain an important market in these three stages of China. At present, its importance is second only to that of the United States. After China's 1 billion people improve diagnosis and disease awareness, including strengthening chronic disease management, China will definitely lead the United States and become the world's largest pharmaceutical market. Therefore, as a market, China will certainly continue to be the most important in the world, no matter in the short term, medium term or long term. As a manufacturing industry, the resilience of China's supply chain in the epidemic has not been disturbed by the COVID-19 epidemic. The government also helps enterprises resume production. Under such circumstances, we can enable China's manufacturing industry to continue to play an important role in the global supply chain. We still need new Chinese drugs to supply the world. Many APIs, including intermediates, are purchased in the middle. Packaging materials and aluminum foil are all purchased in China. All necessary elements related to drugs can be found in China, and they do not need to go anywhere in the world. Therefore, I believe that China is still no problem as a manufacturing center.

The next step is Chinese scientists and Chinese innovation. Tu Youyou won the Nobel Prize for artemisinin, which seems to be the first breakthrough of zero. I believe that in the future, China will follow up on many important medical devices, special foods, nutrition, prevention, the same source of medicine and food, as well as targeted drugs and new drugs.

However, original innovations will continue to emerge in the future. As I mentioned just now, in Beijing Yizhuang, we and Fabrizol made Rosastan, including Worthinib, which is a cooperation with He Huang. These two drugs were invented in China, with patents and intellectual property rights in China. AstraZeneca developed such drugs under the cooperation of AstraZeneca, which was first approved in China and gradually went to the world, Let Chinese patients first use the new drugs invented in China, and let patients around the world gradually use the good drugs invented in China. This will become more and more common in the future. China is not only a market, nor just a manufacturing center, but also a center of scientific innovation. In this way, Chinese innovation will benefit patients all over the world.

OK, thank you, Mr. Wang. Of course, you just mentioned that China, as a big manufacturing country, has inherent advantages in drug manufacturing. At the same time, with the improvement of scientific research level, we will further integrate with the world. What are AstraZeneca's thoughts and actions on R&D innovation and cooperation in the healthy ecosystem?

Because AstraZeneca is a research and development company engaged in innovative drugs, AstraZeneca has brought nearly 40 new drugs to China for 30 years. In the next few years, I think we will launch 20 new drugs before 2030, so there will be 60 new drugs. However, AstraZeneca also realized that drugs are part of the solution to diseases. We strongly believe that food is an important defense line and how to keep people healthy and stable.

How to treat the patients who are not sick and who are not sick should be given a preventive treatment. Traditional Chinese medicine, medicine and food are of the same origin. In addition, in the process of treatment, we should combine artificial intelligence, including auxiliary means, as well as some screening and diagnosis tools, including how to achieve chronic disease management and long-term rehabilitation treatment after treatment. Many diseases will become chronic diseases through treatment and recuperation, including tumors.

As a result, patients are no longer in hospital in an emergency. They spend all their medical resources in the last few months of their lives. This cannot happen again in the future, because this is not our strategic goal of China's 2030 health. Therefore, AstraZeneca is deeply aware that patients need a full course of management, rather than drugs as an answer.

The purpose of creating the ecosystem is to believe that AstraZeneca cannot achieve the goal of 2030 in China. We should unite all the consensus in the whole journey of patients, including companies that can treat diseases, nutrition companies, sports companies, screening companies, AI companies, Chinese medicine companies, chronic disease management companies Digital medical companies are good partners of AstraZeneca.

In the future, there will also be a variety of combination drugs to treat important diseases, rather than a single drug treatment. They will also form joint treatment with other companies. Many drugs will be used cross and jointly to improve the efficacy and reduce adverse reactions. Therefore, in this regard, AstraZeneca realizes that it is not enough to rely on one company. It hopes that AstraZeneca can take the lead in nine treatment fields that AstraZeneca is good at and work with our partners in the entire ecosystem to provide patients with 360 degree comprehensive solutions, which is also an idea of AstraZeneca to build the ecosystem.

Thank you, Mr. Wang. At present, the COVID-19 epidemic still exists. What is the impact of COVID-19 epidemic on our entire industry? At the same time, how will AstraZeneca deal with it in the next step?

In response to the national policy of the COVID-19 epidemic, we have achieved social clearance. I think it is not very convenient for many patients to get medical treatment. Of course, the country has launched many digital medical solutions. The country is also doing a lot of work to strengthen the grass-roots level for patients, and a lot of medical infrastructure is also happening at the grass-roots level. I think that in general practice, as the first line of defense, patients can go to large hospitals without necessarily having minor problems or repeated prescriptions, resulting in a run on medical resources in large hospitals. This is an important key to the epidemic. We should leave resources in large hospitals to patients who really need them, Patients who must undergo hemodialysis can go to large hospitals for treatment, and there is no way. I think because of the epidemic situation, we try not to delay the treatment of these critical patients. AstraZeneca has also actively participated in the research and development of new crown therapeutic drugs and preventive drugs. AstraZeneca's vaccines have also been successfully exported to developing countries in cooperation with Shenzhen Kangtai. Together with the Chinese government, AstraZeneca has played a very important role in helping developing countries fight against the epidemic. AstraZeneca has also actively introduced AstraZeneca's comprehensive antibody drugs for prevention. At present, AstraZeneca has started to treat patients in Hainan first.

In the future, I believe that the normalization of the epidemic situation must be a trend. Xinguan is not a flu. It may exist for a long time. At this time, it is very necessary to protect a small number of vulnerable people. These people have no immunity, and they may not be able to produce immunity after using the vaccine. Of course, most patients should still be vaccinated. A small number of patients, including hemodialysis and transplant patients, including cancer patients undergoing radiotherapy and chemotherapy, need to use comprehensive antibodies to achieve prevention, so as to help a small number of vulnerable people resist diseases, take these therapeutic drugs by mouth, and reduce the mortality of patients with COVID-19 in ICU. I think that if these are well combined, AstraZeneca can actively clean up the future society, including the sustainable fight against the epidemic and the protection of a small number of vulnerable people. AstraZeneca also hopes to play the role of AstraZeneca through the advantages of research and development

At the end, we would also like to invite President Wang to talk about AstraZeneca's future development plan in China? How will we participate in the construction of a healthy China in the next step?

AstraZeneca must be based and rooted in China and become a localized multinational enterprise in China. In the previous stage, China is the second largest market in the world, and this phased task has been achieved. In the next stage, we also regard China as a manufacturing center. At present, drugs made in China have been exported to more than 70 countries around the world, which also helps patients around the world to reduce costs.

Next, we hope to build an ecosystem of whole course management and invest in innovative drugs in China, so that AstraZeneca and innovative enterprises in China can provide innovative solutions and innovative drugs, go to sea together, realize internationalization, and help patients around the world. This is also the next step for us to actively participate in healthy China. I think healthy China must help Chinese patients achieve the goal of healthy China, and let China's innovative medicine and innovative disease management model help patients around the world to build a community of shared future for mankind. I think that as a localized multinational enterprise, AstraZeneca should also maintain a high degree of consistency with the strategy of the Chinese government to actively support the national goal of combating epidemic and health 2030.

Thank you very much, President Wang. Of course, we also hope that China's big market will bring more opportunities for the development of foreign-funded enterprises, and we also hope that enterprises like AstraZeneca can lead the development of the industry in their own areas of advantage for the benefit of all mankind. Thank you again, Mr. Wang, for sharing today. Ladies and gentlemen, that's all for today's People's Hall. Goodbye!